Regency Capital Management Inc. DE Has $6.05 Million Holdings in Danaher Co. (NYSE:DHR)

Regency Capital Management Inc. DE lessened its stake in Danaher Co. (NYSE:DHR) by 4.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,751 shares of the conglomerate’s stock after selling 1,035 shares during the quarter. Danaher comprises approximately 3.3% of Regency Capital Management Inc. DE’s investment portfolio, making the stock its 12th biggest holding. Regency Capital Management Inc. DE’s holdings in Danaher were worth $6,047,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Tsfg LLC grew its position in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares during the period. nVerses Capital LLC bought a new position in Danaher during the 2nd quarter worth approximately $25,000. CarsonAllaria Wealth Management Ltd. bought a new position in Danaher during the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC bought a new position in Danaher during the 1st quarter worth approximately $30,000. Finally, Richardson Financial Services Inc. bought a new position in Danaher during the 4th quarter worth approximately $42,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 over the last ninety days. Insiders own 11.10% of the company’s stock.

Danaher Stock Down 0.2 %

DHR traded down $0.49 during trading on Friday, reaching $270.03. 1,132,662 shares of the stock were exchanged, compared to its average volume of 2,759,666. The stock has a market cap of $200.01 billion, a P/E ratio of 45.78, a price-to-earnings-growth ratio of 4.55 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The stock’s 50 day moving average price is $271.15 and its two-hundred day moving average price is $258.43. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the company earned $2.05 earnings per share. The company’s quarterly revenue was down 2.9% on a year-over-year basis. Equities analysts expect that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s dividend payout ratio is currently 18.31%.

Wall Street Analyst Weigh In

DHR has been the topic of a number of research reports. Evercore ISI lifted their price target on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday. Wells Fargo & Company initiated coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target on the stock. The Goldman Sachs Group lifted their price target on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Stifel Nicolaus lifted their price target on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Finally, Robert W. Baird lifted their price target on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $282.12.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.